GL Stock Analysis — Globe Life
Sector: Financials
AI Verdict
Globe Life trades at 11.3x next year's earnings with just 2.2% growth expected—cheap on P/E, but the high PEG ratio means you're paying up for stability, not expansion, and the moat looks solid but uninspiring for growth.
Competitive Moat
Globe Life specializes in life and supplemental health insurance targeting middle-income Americans, with a defensible moat built on direct-to-consumer distribution and long-standing agent networks. Its entrenched relationships and focus on underserved markets make it difficult for new entrants to dislodge its customer base.
Summary
Globe Life trades at just 11.3x forward earnings, making it one of the cheapest names in insurance for its size.
Where It Stands
Shares are up 24.65% over the past year, the RSI is a neutral 42.3, and the forward P/E of 11.3x is well below the sector median of 14x.
Key Metrics
- RSI: 42.3 — Neutral
- Trailing P/E: 11.6x
- Forward P/E: 11.3x
- PEG Ratio: 5.34
- Earnings Growth: +0.0%
- Revenue Growth: +0.1%
- Market Cap: $13.4B
- Dividend Yield: 0.01%
- 1-Year Return: 24.65%
- 52-Week High: $191.55
- 52-Week Low: $127.85
Analyst Consensus
18 Buy · 5 Hold · 0 Sell (23 analysts)
Bull Case
With a forward P/E of 11.3x and a 2.2% expected EPS growth, investors are paying a modest price for stable, predictable earnings.
Bear Case
If the P/E reverts to the sector median of 14x, upside is limited to about 24%, but the high PEG ratio of 5.34 signals the stock is expensive relative to its growth rate.
Catalyst to Watch
Watch for regulatory changes or shifts in insurance pricing power, as any margin pressure could challenge the low-growth, low-multiple story.